| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $2.01 | - | - |
| Q4'25 | $1.91 | $2.42 | +26.8% |
| Q3'25 | $1.87 | $1.90 | +1.8% |
| Q2'25 | $1.98 | $2.07 | +4.8% |
| Q1'25 | $1.77 | $1.81 | +2.3% |
| Q4'24 | $2.29 | $2.31 | +0.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $2.1B | - | - |
| Q4'25 | $2.1B | $2.2B | +9.0% |
| Q3'25 | - | $2.0B | - |
| Q2'25 | - | $2.1B | - |
| Q1'25 | - | $1.9B | - |
| Q4'24 | - | $2.0B | - |
Market Data
ZBH is currently trading at $91.25, giving Zimmer Biomet Holdings, Inc. a market cap of 17.61B and a P/E ratio of 23.1. Today's range spans $89.23–$91.94, with shares opening at $89.69 and moving down $0.11 (0.1%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 59/100.
Over the past year ZBH has traded between $79.12 and $108.29 - the current price is +15.3% off the 52-week low and -15.7% from the high. 35 analysts cover the stock with a Hold consensus and a mean 12-month target of $98.05 (range $83.00–$130.00), implying upside of +7.5%.
Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, ZBH (55/100, HOLD, price $91.25, in the lower half of its 52-week range) is waiting for that resolution. Sentiment: neutral at 59/100. The current P/E ratio stands at 23.1. With 17.61B in market cap, the 52-week range of $79.12–$108.29 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.
The 52-week range of $79.12–$108.29 for ZBH provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $91.25 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 55/100 and neutral news backdrop (59/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).